Related Experiment Video
Updated: Jun 10, 2026

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
Published on: January 29, 2014
Immune hemolytic anemia associated with drug therapy
1American Red Cross Blood Services, Southern California Region, Pomona, CA 91768, United States. garratty@usa.redcross.org
Abstract:
Drug-induced immune hemolytic anemia (DIIHA) is rare; it can be mild or associated with acute severe hemolytic anemia (HA) and death. About 125 drugs have been implicated as the cause. The HA can be caused by drug-independent antibodies that are indistinguishable, in vitro and in vivo, from autoantibodies causing idiopathic warm type autoimmune hemolytic anemia (AIHA). More commonly, the antibodies are drug-dependent (i.e., will only react in vitro in the presence of the drug). The most common drugs to cause DIIHA are anti-microbials (e.g., cefotetan, ceftriaxone and piperacillin), which are associated with drug-dependent antibodies. The most common drug to cause AIHA is fludarabine. Finding out which drug is causing the problem and stopping that drug is the first approach to therapy. It is not easy to identify the drug interactions accurately in vitro; laboratories specializing in this area can be of great help.
Related Concept Videos
Hypersensitivity Reactions: Cytolytic Reactions
Drug toxicity: Idiosyncratic Reactions
Drug Toxicity: Allergic Reactions
Drug toxicity: Drug–Drug Interaction
Pharmacokinetics: Drug–Drug Interactions
Drug Toxicity: Risk factors
